Advice
In the absence of a submission from the holder of the marketing authorisation
Teriparatide (Forsteo) is not recommended for the treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.
Download detailed advice50KB (PDF)
Medicine details
- Medicine name:
- teriparatide 20 micrograms/80 microlitres, solution for injection, in prefilled pen (Forsteo)
- SMC ID:
- 487/08
- Indication:
- for the treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture
- Pharmaceutical company
- Eli Lilly and Company Ltd
- BNF chapter
- Endocrine system
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 09 June 2008